Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Pharmacopsychiatry

• Publication date

  1998-03-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1055/S-2007-979303PMID 9562213
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient.

  1996cited by this paper
• Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population

  1995cited by this paper
• Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.

  1995cited by this paper
• Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine.

  1993cited by this paper
• Debrisoquine polymorphism: mechanism for very rapid oxidative phenotype.

  1993cited by this paper

• Treatment resistance in psychiatry: state of the art and new directions

  2021cites this paper
• Pharmacokinetics of serotonergic drugs: focus on OCD

  2019cites this paper
• Pain. Part 1: Introduction to pain.

  2015cites this paper
• Implementation of pharmacogenetics in evidence-based medicine: Toward advancing personalized medicine

  2014cites this paper
• Pharmakogenetische Untersuchungen psychiatrischer Patienten: Bestimmung ausgewählter genetischer Varianten in pharmakokinetischen und pharmakodynamischen Strukturen und deren Bedeutung für die Psychopharmakotherapie

  2014cites this paper
• Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

  2013cites this paper
• Patients with Difficult-to-Treat Depression Do not Exhibit an Increased Frequency of CYP2D6 Allele Duplication

  2013cites this paper
• Supplement to: Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

  2013cites this paper
• SEROTONIN IN EMOTIONAL MEMORY PROCESSES: NEUROPHARMACOLOGICAL STUDIES WITH EMPHASIS ON DEPRESSION

  2012cites this paper
• Antidepressant Treatment and Altered CYP2D6 Activity: Are Pharmacokinetic Variations Clinically Relevant?

  2011cites this paper
• Translating pharmacogenetics to primary care

  2011cites this paper
• Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents.

  2009cites this paper
• Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype.

  2008cites this paper
• Defining drug disposition determinants: a pharmacogenetic–pharmacokinetic strategy

  2008cites this paper
• Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence.

  2007cites this paper
• Pharmacogenetics and drug therapy in psychiatry--the role of the CYP2D6 polymorphism.

  2007cites this paper
• GENETICS OF MAJOR DEPRESSIVE DISORDER IN TREATMENT RESISTANCE AND TRYPTOPHAN DEPLETION

  2006cites this paper
• Behavioral and Brain Functions

  2006cites this paper
• Role of Cytochrome P450 Activity in the Fate of Anticancer Agents and in Drug Resistance

  2005cites this paper
• Therapeutisches Drugmonitoring zur Therapieoptimierung

  2005cites this paper
• Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.

  2005influential citation
• Bedeutung von Cytochrom-P450-Polymorphismen für Verlauf, Erfolg und Nebenwirkungen der Therapie mit Antidepressiva

  2005cites this paper
• Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study

  2003cites this paper
• Pharmakokinetik und therapeutisches Monitoring von Antidepressiva

  2002cites this paper
• A patient with treatment‐resistant schizophrenia and cytochrome P4502D6 gene duplication

  2002cites this paper
• Therapy with Antidepressants: Pharmacogenetic Aspects

  2002cites this paper
• Interindividual Variability of the Clinical Pharmacokinetics of Methadone

  2002cites this paper
• Risperidone Metabolism and the Impact of Being a Cytochrome P 450 2 D 6 Ultrarapid Metabolizer

  2002cites this paper
• CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages

  2001cites this paper
• Cytochrome P450 2D6 Genotype and Methadone Steady-State Concentrations

  2001cites this paper
• Letter to the Editor: On the Usefulness of Therapeutic Drug Monitoring of Methadone

  2000cites this paper
• Population Pharmacokinetics of Clomipramine, Desmethylclomipramine, and Hydroxylated Metabolites in Patients With Depression Receiving Chronic Treatment: Model Evaluation

  2000cites this paper
• Venlafaxine and vivid dreaming.

  2000cites this paper